Purpose of Review Our goal is to review the recent literature pertaining to the genetics of sporadic inclusion body myositis (IBM). Recent Findings In a study of 252 IBM patients, the class II MHC allele HLA-DRB1*03:01 showed the most significant association with IBM, and that risk could be largely attributed to amino acids within the peptide-binding pocket. Candidate gene sequencing identified rare missense variants in proteins regulating protein homeostasis including VCP and SQSTM1. An unbiased approach employing exome sequencing of genes encoding rimmed vacuole proteins identified FYCO1 variants in IBM. Ongoing GWAS approaches may shed new light on genetic risk factors for IBM. Summary Many variants have been reported at an increased frequency in IBM in small studies; however, only HLA association has shown genome-wide significance. Future studies are needed to validate variants in larger cohorts and to understand the molecular roles these risk factors play in IBM.
Introduction
Sporadic inclusion body myositis (IBM) is the most common myopathy in individuals over the age of 50, and patients typically lose the ability to ambulate 10 to 15 years after diagnosis [1] [2] [3] . IBM is characterized by slowly progressive asymmetric weakness of both proximal and distal muscles, with the finger flexors and quadriceps typically most affected [4] . Histological features of IBM include rimmed vacuoles, protein aggregates, cytochrome oxidase (COX)-deficient fibers, MHC-I upregulation, and an endomysial inflammatory infiltrate containing autoaggressive CD8+ T cells [4] [5] [6] [7] .
Whether IBM is primarily an autoimmune or a degenerative disease with secondary inflammation is unclear with evidence for both possibilities ( Fig. 1) [8, 9] . The presence of CD8+ T cells invading healthy-appearing myofibers, the association of IBM with specific HLA loci and other autoimmune disorders, and the presence of autoantibodies in IBM support an autoimmune trigger. However, the fact that immunosuppression has failed to show clinical benefit, the lack of inflammation in hereditary inclusion body myopathy (hIBM) that shares other pathologic features with IBM, and the association with aging and protein inclusions found in neurodegenerative disease suggest the possibility that IBM is primarily a degenerative disease. Answering this question is essential for understanding the etiopathogenesis of IBM and developing targeted therapies.
Although rare patients with genetic muscle disease have been reported to have clinical phenotypes indistinguishable from IBM [10, 11] , hIBM typically presents at a younger age than IBM (before age 40), lacks inflammation, and displays a different pattern of muscle weakness [12] . For example, hIBM2 caused by autosomal recessive inheritance of mutations in the GNE gene typically spares the quadriceps, and biopsy shows rimmed vacuoles and protein inclusions but lacks inflammation. Thus, mutations in known hIBM genes cause syndromes that share degenerative features on biopsy This article is part of the Topical Collection on Inflammatory Muscle Disease but otherwise are clinically distinct from IBM. However, classic IBM can occasionally be present within multiple family members ("familial IBM") [13, 14] , strongly supporting a role for genetic risk factors in the development of IBM. The advent of high-throughput sequencing technologies has begun to shed light on how the immune system and degenerative pathways interact in the pathogenesis of IBM.
Immune System
Robust, unbiased genome-wide association studies (GWAS) have not yet been completed in IBM due to the rarity of the disease, though a large multinational effort is underway [15] . Nonetheless, since first described by Garlepp et al. in 1994 , the human leukocyte antigen (HLA) locus has been shown repeatedly to contain the strongest risk alleles for the development of IBM (Table 1) ). This finding is consistent with prior HLA association studies identifying an association of IBM with the 8.1 ancestral MHC haplotype (8.1 AH) [18] [19] [20] 27] . Contrary to previous results that HLA-DRB4 is protective and ameliorates the risk effect of HLA-DRB1*03:01 [25] , no HLA alleles were found to modify disease onset or severity of IBM in this study. Furthermore, in agreement with a study performed in an Australian cohort, there was no distinct HLA association with anti-cytosolic 5′-nucleotidase 1A (anti-cN1A) positivity [26••, 28] .
To investigate whether the risk associated with these HLA-DRB1 alleles could be explained by specific amino acid positions shared between alleles, amino acid imputation was performed. A tyrosine residue at position 26 was found to be more strongly associated with IBM (p < 5.22 × 10
) than the HLA-DRB1 allele alone, and an additional independent effect was seen at position 11 (p < 3.8 × 10
) for serine. Of note, previous studies have associated positions 11 and 26 with other autoimmune diseases such as systemic lupus erythematosus [29] . Both of these residues are located within the β-sheet floor of DR β-chain 1 that forms part of the peptidebinding groove and may influence peptide binding and predispose individuals to autoimmunity [26••] . Interestingly, although HLA-DRB1*03:01 is also a significant risk factor for polymyositis (PM) and dermatomyositis (DM), amino acid position 74 explains almost all of the risk within the allele for PM and DM [30•] .
NOTCH4, a previously identified risk gene within the HLA locus [31] , was not explicitly examined in this study due to its strong linkage disequilibrium with the 8. ) included a known frameshift mutation in CCR5 that causes a nonfunctional receptor [26••] . CCR5 (C-C Chemokine Receptor type 5) is an important regulator of T cell migration, suggesting a potential role for chemokines in the pathogenesis of IBM. A recent case-control study analyzing whole exome sequencing data on 30 Finnish IBM patients identified seven SNPs found at > 2-fold higher frequency in IBM and, in addition to the HLA locus, implicated genes that regulate sphingolipid transport as potential IBM risk factors [24•] .
Overall, these recent studies have confirmed that variants within the HLA locus are risk factors for developing IBM, perhaps the strongest evidence to date that the immune system plays a causative role in IBM.
Proteostasis
Both IBM and inherited inclusion body "myopathy" syndromes share degenerative myopathic features on biopsy including rimmed vacuoles, ubiquitinated protein aggregates, and 15-18 nm tubulofilamentous "inclusions" observed with electron microscopy. A known cause of this pathology shared with many degenerative diseases is disruption of protein homeostasis, or proteostasis, as can be caused by impairment of the proteasome or autophagy. For example, inclusion body myopathy with Paget's disease and frontotemporal dementia (IBMPFD) is a multisystem degenerative disease caused by autosomal dominant inheritance of missense mutations in Fig. 1 Models of IBM pathogenesis. In the degenerative model, disrupted proteostasis (A) leads to muscle degeneration and atrophy, and inflammation (B) is secondary to abnormal antigen presentation by muscle cells. In the autoimmune model, refractory autoimmune cells (C) secrete factors that cause protein aggregation (D), and these processes cause muscle degeneration and atrophy valosin-containing protein (VCP) [32] . VCP, also called p97 or cdc48, is a highly conserved homohexameric ATPase that functions as a "segregase" to remove ubiquitinated proteins from macromolecular complexes and thus plays an important role in proteostasis [33] .
Intriguingly, rare VCP variants have recently been implicated in IBM as well as multiple neurodegenerative diseases including frontotemporal dementia (FTD), Parkinson's disease, amyotrophic lateral sclerosis (ALS), and CharcotMarie-Tooth disease [34] [35] [36] [37] [38] . Rare mutations in other genes, including HNRPA1, HNRPA2B1, and SQSTM1, have also been found to cause similar autosomal dominantly inherited degenerative diseases affecting the muscle, bone, and brain and have been termed "multisystem proteinopathy," or MSP [39] . As with hIBM, MSP patients usually present before age 40 without the typical IBM pattern of weakness, and affected muscles in MSP display rimmed vacuoles and protein inclusions but lack inflammation. However, recent findings suggest that rare variants in these MSP genes may increase the risk for developing IBM. Using targeted next-generation sequencing, Weihl et al. screened a cohort of 79 IBM patients for variants in 38 genes associated with muscular dystrophies, myopathies, ALS, and dementia [40• ]. This candidate-based approach uncovered an increased frequency of rare variants in multiple genes including VCP, SQSTM1, FLNC, ZASP, and BAG3 as well as a novel variant in HNRPA2B1. FLNC, SQSTM1, ZASP, and BAG3 are known to be mutated in rare inherited vacuolar myopathies and also play integral roles in the autophagy pathway [41] [42] [43] . SQSTM1 (Sequestosome 1, also known as p62) is a ubiquitin-binding autophagy adaptor that has been shown to label protein inclusions in IBM muscle [44] [45] [46] . The two rare variants identified in VCP were previously reported as putative disease-associated variants [36, 47, 48] , and expression of these variants in cell culture causes an accumulation of the autophagosome markers p62 and LC3-II, suggestive of a disruption in autophagy [49] . Similarly, other candidate-based whole exome sequencing (WES) approaches have also identified rare VCP variants in IBM in addition to SQSTM1 [50••] and ZASP [51] . The majority of these variants are in evolutionarily conserved regions, suggesting that they may have functional consequences and increase risk for disease. However, given the selection bias inherent in candidatebased approaches, further studies are necessary to determine whether these variants significantly alter protein function and play a role in IBM pathogenesis.
Rather than starting with genes previously implicated in muscle disease, Güttsches et al. performed an unbiased proteomics approach to identify proteins enriched in rimmed vacuoles (RVs) [52••] . This method led to the identification of 213 proteins, 40 of which had been previously described in IBM including VCP and p62, validating this approach. Interestingly, proteins involved in protein quality control were among the most abundantly overrepresented proteins. To look for novel genetic contributors to IBM, WES was used to identify variants in genes encoding proteins found in RVs. When comparing the burden of these variants to an ALS cohort, only variants in the FYCO1 gene were statistically enriched in IBM patients (11.3 vs. 2.6% in controls). FYCO1 has been implicated in microtubule transport of autophagosomes, consistent with a role for autophagy impairment in the pathogenesis of IBM [53] .
These recent studies all suggest that rare variants in proteins regulating autophagy and protein degradation may contribute to IBM risk. A recent study evaluated the therapeutic potential of targeting protein aggregation in IBM with arimoclomol [54] . Arimoclomol is a small molecule thought to upregulate chaperone expression in stressed cells, thereby reducing the formation of protein aggregates. In myoblast cells and mice expressing mutant VCP protein, arimoclomol improved IBM-like pathology, and in a small proof-ofconcept clinical study, there was a trend toward reduced decline in muscle strength and physical function in IBM patients taking arimoclomol compared to placebo. A multisite phase II clinical trial is underway to evaluate the efficacy of this drug in IBM.
Mitochondria
Mitochondrial pathology has long been recognized as a prominent feature of IBM, including myofibers that accumulate abnormal mitochondria, COX-deficient fibers, and mitochondrial DNA (mtDNA) deletions [55] [56] [57] . Using real-time PCR, COX-deficient fibers from IBM patients were shown to have higher mtDNA deletion loads when compared to COXnormal fibers [55] , supporting previous work that correlated mtDNA deletion load and COX-deficient fiber proportion. Interestingly, the fraction of COX-deficient fibers correlated with the amount of infiltrating T lymphocytes, suggesting an interaction between the mitochondrial defect and the autoimmune component of IBM [58] .
Another mitochondrial protein that has been investigated in IBM is the translocase of outer mitochondrial membrane 40 (TOMM40). TOMM40 lies adjacent to apolipoprotein E (ApoE) in the genome, and thus ApoE and TOMM40 alleles are co-inherited. Prior studies have shown that the ApoE and TOMM40 genotype combination can be used as a predictor of age-dependent risk in Alzheimer's disease (AD) [59] . Given the reported β-amyloid deposition in both IBM and AD, Mastaglia et al. investigated ApoE and TOMM40 polymorphisms in IBM [60] . In a study of 90 Caucasian patients, they found that carriers of APOE ε3 who also contained the very long (VL) poly-T repeat allele of TOMM40 had a reduced risk of developing IBM as well as a later age of onset. Recently, Gang et al. investigated this further in a larger cohort of 158 IBM patients obtained through the International IBM Genetics Consortium [61] . In contrast to the previous study, they did not find an association between any particular APOE-TOMM40 genotype and the risk of developing IBM, but did find that individuals carrying the VL TOMM40 allele had a later age of onset [61] . Since both studies found that the TOMM40 VL allele delays IBM disease onset, these findings suggest that further investigation into how the VL allele alters TOMM40 and mitochondrial function may shed insight into IBM pathogenesis.
Gene Therapy
Recent success in clinical trials of gene therapy in spinal muscular atrophy (SMA) [62, 63] , an inherited motor neuron disease, in addition to excitement around genome editing technologies such as CRISPR [64] has led to the consideration of gene therapy for IBM. Since muscle atrophy is a major part of IBM pathology, Greenberg and colleagues analyzed the myostatin signaling pathway in IBM muscle. Myostatin is a tumor growth factor beta (TGF-β) family member that has a well-defined role as a negative regulator of muscle mass, making it a promising therapeutic target for muscle wasting disorders [65] . In particular, gene therapy using follistatin, a natural inhibitor of the myostatin receptor, has been reported to be safe and cause muscle hypertrophy in mice and primates [66] . Since the myostatin signaling pathway was reported to be upregulated in IBM [67] , follistatin gene therapy has been tested to determine if it improves muscle strength and function in IBM.
In a recent phase 1/2a clinical trial, adeno-associated viral (AAV) delivery of follistatin isoform 344 (FS344) via intramuscular quadriceps injection was reported to modestly improve the distance traveled for a 6-min walk test (6MWT) in a small cohort of Becker muscular dystrophy (BMD) patients [68] . Promising histological changes were also observed including reduced endomysial fibrosis, fewer centralized nuclei, and normalization of fiber size. In a "proof-of-principle" trial, six male IBM patients received bilateral intramuscular quadriceps injections of AAV1 vectors carrying FS344 [69] . One noteworthy change from the BMD study is that the IBM study included an exercise regimen for each participant as it had been demonstrated that exercise increased plasma levels of follistatin [70] . This study observed an improvement in the distance traveled for a 6MWT, and all post-treatment biopsies showed increased number of muscle fibers [69] . However, significant concerns have been raised with regard to the design of this trial and the authors' claim of efficacy [71] . Most importantly, the lack of a control group makes it difficult to determine how much of the improvement was a result of exercise and/or placebo effect. Although previously it had been thought that exercise did not significantly alter the natural history of IBM, several studies suggest beneficial effects of endurance exercise in IBM patients [72] [73] [74] [75] .
Conclusion
IBM is a multifactorial disease with both inflammatory and degenerative characteristics. New high-throughput sequencing methods have revolutionized genetic analyses of complex disease, allowing for identification of genetic variants that are associated with an increased risk of developing IBM. Recent studies have confirmed and refined the major role the HLA locus plays in IBM susceptibility, strongly implicating autoimmunity in disease pathogenesis. In addition, multiple studies have identified rare variants within genes known to regulate protein quality control including autophagy, suggesting that one's ability to prevent protein aggregate formation may partially underlie disease risk. While intriguing, the rare nature of IBM and the presence of most of these variants at low levels in the population make the significance of these findings unclear.
The identification of both immune-and proteostasis-related genes in disease susceptibility of IBM further implicates both processes in IBM pathogenesis (Fig. 1) . In the degenerative model, a combination of genetic and environmental factors during aging may lead to defects in proteostasis (A) resulting in abnormal antigen presentation by muscle cells. This, in turn, may trigger an inflammatory response with T cell invasion (B), and inflammation may or may not contribute to muscle degeneration and atrophy. In the autoimmune model, these same initial factors may first trigger autoimmunity (C), and the persistent inflammatory milieu may then lead to the development of protein aggregation (D), which may or may not contribute to muscle degeneration and atrophy. It is entirely possible that both models are correct and that the initiating process may vary in different patients. Since both inflammatory and degenerative processes interact in IBM, therapeutically targeting both may ultimately prove most successful.
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